HC Wainwright reissued their buy rating on shares of Sana Biotechnology (NASDAQ:SANA – Free Report) in a report published on Wednesday,Benzinga reports. They currently have a $8.00 price objective on the stock.
A number of other equities analysts have also weighed in on the company. JMP Securities lowered Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research note on Tuesday, November 5th. Citigroup upped their price objective on Sana Biotechnology from $8.00 to $15.00 and gave the stock a “buy” rating in a research note on Friday, August 9th.
View Our Latest Stock Analysis on SANA
Sana Biotechnology Stock Up 9.0 %
Sana Biotechnology (NASDAQ:SANA – Get Free Report) last released its quarterly earnings data on Friday, November 8th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.01. Research analysts expect that Sana Biotechnology will post -1.16 EPS for the current fiscal year.
Insider Buying and Selling
In related news, Director Richard Mulligan sold 150,000 shares of the business’s stock in a transaction dated Tuesday, September 24th. The stock was sold at an average price of $4.08, for a total value of $612,000.00. Following the sale, the director now directly owns 2,848,121 shares in the company, valued at approximately $11,620,333.68. The trade was a 5.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 31.10% of the stock is owned by company insiders.
Institutional Investors Weigh In On Sana Biotechnology
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SANA. Wilmington Savings Fund Society FSB purchased a new stake in Sana Biotechnology during the third quarter valued at approximately $29,000. Stifel Financial Corp purchased a new stake in Sana Biotechnology during the third quarter valued at approximately $43,000. EP Wealth Advisors LLC purchased a new stake in Sana Biotechnology during the third quarter valued at approximately $45,000. Blue Trust Inc. raised its position in Sana Biotechnology by 1,246.6% during the third quarter. Blue Trust Inc. now owns 13,129 shares of the company’s stock valued at $55,000 after purchasing an additional 12,154 shares during the period. Finally, Cornercap Investment Counsel Inc. purchased a new stake in Sana Biotechnology during the third quarter valued at approximately $67,000. 88.23% of the stock is currently owned by hedge funds and other institutional investors.
Sana Biotechnology Company Profile
Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.
Featured Stories
- Five stocks we like better than Sana Biotechnology
- Most Volatile Stocks, What Investors Need to Know
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- Breakout Stocks: What They Are and How to Identify Them
- 3 Penny Stocks Ready to Break Out in 2025
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for Sana Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sana Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.